Biomarkers are indicators that can determine the occurrence, development and prognosis of diseases, and play an important role in early diagnosis, disease prevention, drug target confirmation, and drug response. Biomarker detection can provide insight into the mechanism of action or resistance of new drugs in disease models.
Medicilon can provide detection services for cytokines and biomarkers for the majority of pharmaceutical R & D personnel. Its biological analysis department has complete infrastructure and advanced instruments and equipment. It has high-end technology platforms such as flow CBA, MSD and Luminex systems, which can detect various single plex or multiple forms of cytokines and biomarkers.
At Medicilon, we have over 10 years’ experience in biomarker analysis services and we operate two of our own GLP laboratories. We provide biomarker testing and analysis services to support preclinical research of new therapeutics. We perform biomarker assay development and validation using single and multiplex LC/MS/MS, MSD, ELISA, and enzyme activity techniques.
Our highly knowledgeable team has experience in the development of the following biomarkers:
LC/MS/MS Biomarker Assays: Medicilon develops and validates highly selective bioanalytical methods for the simultaneous quantitation of multiple biomarker peptides or epitope peptides of monoclonal antibodies in serum or plasma matrices coupled with UPLC/MS/MS.
ELISA Biomarker Assays: We can provide biomarker testing and analysis services to support preclinical diagnostic research of new therapeutics. We perform biomarker assay development, validation and profiling of disease panels using ELISA technique.
The validation process results in a comprehensive data packet that is reviewed by quality assurance personnel, who ensure that the test results meet established procedures.
These procedures require that:
– Controls meet established specifications
– Non-specific binding, low standard, and high standard signals meet the established specifications
– Sensitivity, determined by assaying multiple replicates of the zero standard, falls within the established specifications
– Standards match master calibrators within the established specifications
Biomarkers are molecular substances in the body that can be used to indicate health or disease. These biomarkers can be found in tissue, blood, urine and other body fluids. This effort focuses on three types of biomarker discovery: protein biomarkers in tissues and cells, bodily fluid (blood, urine, and other fluids) protein biomarkers, and transcriptome (RNA) biomarkers.
Tissue Proteins
Cell and tissue analysis of cancer specimens allows researchers to assess the exact site and expression level of protein cancer biomarkers in architecturally preserved or homogenized tissues. Analysis can include histomorphological examination in collaboration with a pathologist, use of immunohistochemical staining with specific antibodies on cell and whole mount tissue specimens, and Western blot analysis of cell or tissue homogenates.
Fluid Proteins
The emerging field of proteomics provides new tools for the early detection of cancer from human serum, cerebral spinal fluid, urine and other complex samples. Proteomic research provides information regarding the proteome’s dynamic and rapid changes which result from exogenous exposure or endogenous factors. The CTCR Core offers a fee-per-service proteomic analysis based on the patented Surface Enhanced Laser Desorption/Ionization (SELDI) technology, Ciphergen’s ProteinChip® System. Assays using SELDI time-of-flight mass spectrometry (TOF-MS) to provide a means to identify new candidate biomarker proteins because of their ability to detect and quantify multiple post-translationally modified and processed protein forms in a single assay. The ability to interface ProteinChip® Arrays with tandem mass spectrometry allows for direct amino acid sequencing from ProteinChip experiments. ProteinChip arrays require only microliter volumes of sera, cell extracts, or tissue lysates for analysis.
RNA Molecules
New methods to analyze gene expression or the “transcriptome” of cancer cells for comparison to the patterns of normal cells provides a powerful new means of identifying RNA biomarkers for specific cancers. Several research projects are underway using the core facilities available to CTCR researchers. These projects seek to analyze total expressed RNA using microarrays, microRNAs that function as regulators of protein expression, quantitative analysis of single genes using Q-PCR, and to develop new methods to analyze RNA expression in archived cancer tissue specimens.
- Luminex multiplex Assay;
- MSD multiplex Assay;
- FACS CBA multiplex Assay;
- AlphaLISA;
- Single plex ELISA, etc.
- Tumor research: tumor marker detection, HPV detection;
- vaccine research;
- Drug efficacy evaluation, drug development;
- Concentration detection of cytokines, inflammatory factors, chemokines, enzymes, etc.;
- Quantitative analysis of phosphorylated proteins and apoptosis-related proteins in cell signaling;
- Autoimmune function analysis, etc.;
- Epidemiological surveillance;
- HLA typing test;
- Cardiovascular disease research;
- Diabetes and metabolic disease research;
- Signal pathway research;
- Gene mutation research, etc.
Email : marketing@medicilon.com
Tel : +86 021 58591500
Tips: Above is part of biomarker discovery, biomarker testing and biomarker analysis. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.
1. PDK4 gene can be used as a biomarker for the treatment of prostate cancer
2. Peripheral Protein Signaling May Help Early Diagnosis of Alzheimer's Disease
3. Analysis of APC Gene, a Biomarker of Colon Cancer
4. Kidney Cancer Biomarker Predicts Disease Risk and Survival
5. Biomarker´s Potential for Diagnosing Traumatic Brain Injury Solidified
6. Zika Biomarkers Could Lead to Prenatal Diagnostic
7. Lung Cancer Biomarker Discovery Raises Hopes for Early Detection
marketing@medicilon.com
